|
1
|
Knight CL and Nelson-Piercy C: Management
of systemic lupus erythematosus during pregnancy: Challenges and
solutions. Open Access Rheumatol. 8:23–36. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ngo ST, Steyn FJ and McCombe PA: Gender
differences in autoimmune disease. Front Neuroendocr. 35:347–369.
2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Petri M: Pregnancy and systemic lupus
erythematosus. Best Pract Res Clin Obstet Gynaecol. 64:24–30.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wind M, Fierro JJ, Bloemenkamp KWM, de
Leeuw K, Lely AT, Limper M, Sueters M, Teng YKO, Walter IJ and
Kooiman J: Pregnancy outcome predictors in systemic lupus
erythematosus: A systematic review and meta-analysis. Lancet
Rheumatol. 6:e667–e683. 2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Society for Maternal-Fetal Medicine
(SMFM). Electronic address: pubs@smfm.org. Silver R, Craigo S,
Porter F, Osmundson SS, Kuller JA and Norton ME: Society for
maternal-fetal medicine consult series #64: Systemic lupus
erythematosus in pregnancy. Am J Obstet Gynecol. 228:B41–B60.
2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Clowse MEB, Eudy AM, Balevic S,
Sanders-Schmidler G, Kosinski A, Fischer-Betz R, Gladman DD, Molad
Y, Nalli C, Mokbel A, et al: Hydroxychloroquine in the pregnancies
of women with lupus: A meta-analysis of individual participant
data. Lupus Sci Med. 9(e000651)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gamba A, Zen M, Depascale R, Calligaro A,
Gatto M, Iaccarino L and Doria A: Modern management of pregnancy in
systemic lupus erythematosus: From prenatal counseling to
postpartum support. J Clin Med. 13(3454)2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sammaritano LR, Bermas BL, Chakravarty EE,
Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW,
Buyon J, et al: 2020 American College of Rheumatology guideline for
reproductive health in rheumatic diseases. Arthritis Rheumatol.
72:529–556. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Dao KH and Bermas BL: Systemic lupus
erythematosus management in pregnancy. Int J Womens Health.
14:199–211. 2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fanouriakis A, Kostopoulou M, Andersen J,
Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria
A, et al: EULAR recommendations for the management of systemic
lupus erythematosus: 2023 update. Ann Rheum Dis. 83:15–29.
2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rubin RL: Drug-induced lupus. In: Wallace
DJ, Hahn BH, (eds.): Dubois' Lupus Erythematosus and Related
Syndromes. 9th edition. Elsevier, 2019.
|
|
12
|
Kim JW, Kim HA, Suh CH and Jung JY: Sex
hormones affect the pathogenesis and clinical characteristics of
systemic lupus erythematosus. Front Med (Lausanne).
9(906475)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fanouriakis A, Tziolos N, Bertsias G and
Boumpas DT: Update on the diagnosis and management of systemic
lupus erythematosus. Ann Rheum Dis. 80:14–25. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Andreoli L, Chighizola CB, Iaccarino L,
Botta A, Gerosa M, Ramoni V, Tani C, Bermas B, Brucato A, Buyon J,
et al: Immunology of pregnancy and reproductive health in
autoimmune rheumatic diseases. Autoimmun Rev.
22(103259)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tarter L and Bermas BL: Expert perspective
on a clinical challenge: Lupus and pregnancy. Arthritis Rheumatol.
76:321–331. 2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW
and Suh CH: Lupus low disease activity state achievement is
important for reducing adverse outcomes in pregnant patients with
systemic lupus erythematosus. J Rheumatol. 48:707–716.
2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tani C, Zucchi D, Haase I, Larosa M,
Crisafulli F, Strigini FAL, Monacci F, Elefante E, Mucke J, Choi
MY, et al: Are remission and low disease activity state ideal
targets for pregnancy planning in systemic lupus erythematosus? A
multicentre study. Rheumatology (Oxford). 60:5610–5619.
2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Larosa M, Costedoat-Chalumeau N,
Guettrot-Imbert G, Le Guern V, Morel N, Jesus D, Iaccarino L, Inês
L and Doria A: SLE-DAS in the first trimester of gestation predicts
maternal lupus flares later in pregnancy. Front Pharmacol.
12(660123)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Murata T, Kyozuka H, Fukuda T, Toba N,
Kanno A, Yasuda S, Yamaguchi A, Nomura Y, Kanno T, Migita K and
Fujimori K: Maternal disease activity and serological activity as
predictors of adverse pregnancy outcomes in women with systemic
lupus erythematosus: A retrospective chart review. Arch Gynecol
Obstet. 305:1177–1183. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sims CA, Eudy AM, Doss J, Rogers JL, Sadun
RE, Criscione-Schreiber L, Sun K and Clowse ME: The impact of
pregnancy planning and medical readiness on reproductive outcomes
in women with systemic lupus erythematosus. Lupus. 32:1666–1674.
2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
McDonald EG, Bissonette L, Ensworth S,
Dayan N, Clarke AE, Keeling S, Bernatsky S and Vinet E: Monitoring
of systemic lupus erythematosus pregnancies: A systematic
literature review. J Rheumatol. 45:1477–1490. 2028.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Morales-Martinez FA, Salas-Castro C,
García-Garza MR, Valdés-Martínez O, García-Luna SM, Garza-Elizondo
M, Vidal-Gutiérrez O, Saldívar-Rodríguez D and Sordia-Hernández LH:
Evaluation of the ovarian reserve in women with systemic lupus
erythematosus. J Fam Reprod Health. 15:38–44. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ejaz K, Abid D, Juneau P, Chu J and Hasni
S: Use of gonadotropin-releasing hormone agonists for ovarian
preservation in patients receiving cyclophosphamide for systemic
lupus erythematosus: A meta-analysis. Lupus. 31:1706–1713.
2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Morand EF, Furie R, Tanaka Y, Bruce IN,
Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, et
al: Trial of anifrolumab in active systemic lupus erythematosus. N
Engl J Med. 382:211–221. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Petri M, Kim MY, Kalunian KC, Grossman J,
Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM,
Askanase AD, et al: Combined oral contraceptives in women with
systemic lupus erythematosus. N Engl J Med. 353:2550–2558.
2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Stamm B, Barbhaiya M, Siegel C, Lieber S,
Lockshin M and Sammaritano L: Infertility in systemic lupus
erythematosus: What rheumatologists need to know in a new age of
assisted reproductive technology. Lupus Sci Med.
9(e000840)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Moyer A and Edens C: Impact of systemic
lupus erythematosus on conception: Insights into infertility,
fertility preservation, assisted reproductive technology, and
pregnancy outcomes. Semin Reprod Med. 42:209–227. 2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
de Jesus GR, Lacerda MI, Rodrigues BC, Dos
Santos FC, do Nascimento AP, Cristóvão Porto L, de Jesús NR, Levy
RA and Klumb EM: Soluble Flt-1, placental growth factor, and
vascular endothelial growth factor serum levels to differentiate
between active lupus nephritis during pregnancy and preeclampsia.
Arthritis Care Res Hoboken. 73:717–721. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hirashima C, Ogoyama M, Abe M, Shiraishi
S, Sugase T, Niki T, Matsubara S and Ohkuchi A: Clinical usefulness
of serum levels of soluble fms-like tyrosine kinase 1/placental
growth factor ratio to rule out preeclampsia in women with
new-onset lupus nephritis during pregnancy. CEN Case Rep. 8:95–100.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jiang Y, Tao M, Chen J, Luo L, You Q, Wu H
and Zhang N: Calcineurin inhibitors in the treatment of systemic
lupus erythematosus during pregnancy: A narrative review with
emphasis on efficacy and safety. Eur J Obstet Gynecol Reprod Biol.
294:148–15. 2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gryka-Marton M, Szukiewicz D,
Teliga-Czajkowska J and Olesinska M: An overview of neonatal lupus
with anti-Ro characteristics. Int J Mol Sci.
22(9281)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Garcia S and Campos-de-Carvalho AC:
Neonatal lupus syndrome: The heart as a target of the immune
system. Acad Bras Cienc. 72:83–89. 2007.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Izmirly P, Kim M, Friedman DM,
Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF,
Cohen RE, Robins K, et al: Hydroxychloroquine to prevent recurrent
congenital heart block in fetuses of anti-SSA/Ro-positive mothers.
J Am Coll Cardiol. 76:292–302. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bremme K, Honkanen S, Gunnarsson I and
Chaireti R: The presence of lupus nephritis additionally increases
the risk of preeclampsia among pregnant women with systemic lupus
erythematosus. Lupus. 28:1013–1021. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Moroni G, Calatroni M and Ponticelli C:
The impact of preeclampsia in lupus nephritis. Expert Rev Clin
Immunol: May 10:1-13, 2022 doi: 10.1080/1744666X.2022.2074399 (Epub
ahead of print).
|
|
36
|
Huang J, Zhu Q, Wang B, Wang H, Xie Z, Zhu
X, Zhao T and Yang Z: Antiphospholipid antibodies and the risk of
adverse pregnancy outcomes in patients with systemic lupus
erythematosus: A systematic review and meta-analysis. Expert Rev
Clin Immunol. 20:793–801. 2024.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Tektonidou MG, Andreoli L, Limper M,
Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T,
Ferrer-Oliveras R, Hambly K, et al: EULAR recommendations for the
management of antiphospholipid syndrome in adults. Ann Rheum Dis.
78:1296–1304. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Vaught AJ, Gavriilaki E, Hueppchen N,
Blakemore K, Yuan X, Seifert SM, York S and Brodsky RA: Direct
evidence of complement activation in HELLP syndrome: A link to
atypical hemolytic uremic syndrome. Exp Hematol. 44:990–998.
2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Smyth A, Oliveira GH, Lahr BD, Bailey KR,
Norby SM and Garovic VD: A systematic review and meta-analysis of
pregnancy outcomes in patients with systemic lupus erythematosus
and lupus nephritis. Clin J Am Soc Nephrol. 51:2060–2068.
2010.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yelnik CM, Laskin CA, Porter TF, Branch
DW, Buyon JP, Guerra MM, Lockshin MD, Petri M, Merrill JT,
Sammaritano LR, et al: Lupus anticoagulant is the main predictor of
adverse pregnancy outcomes in aPL-positive patients: Validation of
PROMISSE study results. Lupus Sci Med. 3(e000131)2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Stone S, Pijnenborg R, Vercruysse L,
Poston R, Khamashta MA, Hunt BJ and Poston L: The placental bed in
pregnancies complicated by primary antiphospholipid syndrome.
Placenta. 27:457–467. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Di Ludovico A, Rinaldi M, Mainieri F, Di
Michele S, Girlando V, Ciarelli F, La Bella S, Chiarelli F,
Attanasi M, Mauro A, et al: Molecular mechanisms of fetal and
neonatal lupus: A narrative review of an autoimmune disease
transferal across the placenta. Int J Mol Sci.
25(5224)2024.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lun Hon K and Leung AK: Neonatal lupus
erythematosus. Autoimmune Dis. 2012(301274)2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Andreoli L, Bertsias GK, Agmon-Levin N,
Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R,
Forger F, Moraes-Fontes MF, et al: EULAR recommendations for
women's health and the management of family planning, assisted
reproduction, pregnancy and menopause in patients with systemic
lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum
Dis. 76:476–485. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yamamoto Y and Aoki S: Systemic lupus
erythematosus: Strategies to improve pregnancy outcomes. Int J
Womens Health. 8:265–272. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Götestam Skorpen C, Hoeltzenbein M,
Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J,
Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, et al: The EULAR
points to consider for use of antirheumatic drugs before pregnancy
and during pregnancy and lactation. Ann Rheum Dis. 75:795–810.
2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kemp MW, Newnham JP, Challis JG, Jobe AH
and Stock SJ: The clinical use of corticosteroids in pregnancy. Hum
Reprod Update. 22:240–259. 2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lateef A and Petri M: Systemic lupus
erythematosus and pregnancy. Rheum Clin North Am. 43:215–226.
2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
US Food and Drug Administration: FDA
recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later
because they can result in low amniotic fluid: NSAIDs may cause
rare kidney problems in unborn babies, 2020.
|
|
50
|
Di Prima FA, Valenti O, Hyseni E, Giorgio
E, Faraci M, Renda E, De Domenico R and Monte S: Antiphospholipid
syndrome during pregnancy: The state of the art. J Prenat Med.
5:41–53. 2011.PubMed/NCBI
|
|
51
|
Schreiber K and Hunt BJ: Managing
antiphospholipid syndrome in pregnancy. Thromb Res. 181 (Suppl
1):S41–S46. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Nori W, Akram NN and Al-Ani RM: Update on
hydroxychloroquine use in pregnancy. World J Exp Med. 13:99–101.
2023.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Hu Z, Gao R, Huang W, Wang H and Qin L:
Effect of hydroxychloroquine on lupus activity, preeclampsia and
intrauterine growth restriction in pregnant women with systemic
lupus erythematosus and/or antiphospholipid syndrome: A systematic
review and meta-analysis. J Clin Med. 12(485)2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Duan J, Ma D, Wen X, Guo Q, Gao J, Zhang
G, Xu K and Zhang L: Hydroxychloroquine prophylaxis for
preeclampsia, hypertension and prematurity in pregnant patients
with systemic lupus erythematosus: A meta-analysis. Lupus.
30:1163–1174. 2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Nørgård B, Pedersen L, Fonager K,
Rasmussen SN and Sørensen HT: Azathioprine, mercaptopurine and
birth outcome: A population-based cohort study. Aliment Pharmacol
Ther. 17:827–834. 2023.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Natekar A, Pupco A, Bozzo P and Koren G:
Safety of azathioprine use during pregnancy. Can Fam Physician.
57:1401–1402. 2011.PubMed/NCBI
|
|
57
|
Perez-Aytes A, Marin-Reina P, Boso V, Ledo
A, Carey JC and Vento M: Mycophenolate mofetil embryopathy: A newly
recognized teratogenic syndrome. Eur J Med Genet. 61:16–21.
2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Merlob P, Stahl B and Klinger G: Tetrada
of the possible mycophenolate mofetil embryopathy: A review. Reprod
Toxicol. 28:105–108. 2009.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Jackson P, Paquette L, Watiker V, Randolph
L, Ramanathan R and Seri I: Intrauterine exposure to mycophenolate
mofetil and multiple congenital anomalies in a newborn: Possible
teratogenic effect. Am J Med Genet A. 149A:1231–1236.
2009.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zhu Q, Wang J, Sun Q, Xie Z, Li R, Yang Z,
Song Z, Yang K and Zhao T: Effect of hydroxychloroquine on
pregnancy outcome in patients with SLE: A systematic review and
meta-analysis. Lupus Sci Med. 11(e001239)2024.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Rovin BH, Teng YKO, Ginzler EM, Arriens C,
Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, et
al: Efficacy and safety of voclosporin versus placebo for lupus
nephritis (AURORA 1): A double-blind, randomised, multicentre,
placebo-controlled, phase 3 trial. Lancet. 397:2070–2080.
2021.PubMed/NCBI View Article : Google Scholar
|
